Patents by Inventor Ryutaro Asano
Ryutaro Asano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230407876Abstract: A fan includes an impeller including a boss and a plurality of blades; an air guide portion through which an airflow moves from one end to the other end of the air guide portion; and a bell mouth defining a first suction passage inside the bell mouth and defining, together with an inner surface of the air guide portion, a second suction passage outside the bell mouth. Between an upstream end point located in an inlet of the first suction passage and a downstream end point located in an outlet of the first suction passage of the bell mouth, the bell mouth includes a minimum possible radius point to which a distance, in a radial direction, from a rotation axis of the boss is smaller than a distance, in the radial direction, from the rotation axis to the downstream end point.Type: ApplicationFiled: December 23, 2020Publication date: December 21, 2023Applicant: Mitsubishi Electric CorporationInventors: Tomoya FUKUI, Makoto TANISHIMA, Ryutaro ASANO, Kisho HATAKENAKA, Kenichi SAKODA
-
Publication number: 20230332615Abstract: In a turbofan, a first curve, formed by projecting a leading edge onto a plane perpendicular to a rotating shaft, has a first inflection point and has a portion that is convex at a point closer to the first inflection point than the first point is in a counter-rotational direction and a portion that is convex at a point closer to the second point than the first inflection point is in the rotational direction, the first point is located forward of the second point in the rotational direction, a second curve, formed by projecting the trailing edge onto a plane perpendicular to the rotating shaft, follows an arc centered on the rotating shaft in a top view, a third curve, formed by projecting the trailing edge onto a cylindrical plane coaxial with the rotating shaft, is formed so as to be convex in the rotational direction, and a junction point of the third curve and the shroud is located behind the junction point of the third curve and the main plate in the rotational direction.Type: ApplicationFiled: November 25, 2020Publication date: October 19, 2023Applicant: Mitsubishi Electric CorporationInventors: Ryutaro ASANO, Tomoya FUKUI, Kazuki ISOMURA, Makoto KURIHARA
-
Publication number: 20170274072Abstract: To provide bispecific antibodies and highly functional bispecific antibodies, which are produced by using a new anti-human EGF receptor 1 (Her 1) antibody different from the antibody 528. A bispecific antibody, comprising a variable region of the light chain (2L: SEQ ID NO:2) and a variable region of the heavy chain (2H: SEQ ID NO:4) of an anti-human EGF receptor 1 antibody 225, and a humanized variable region of the light chain (OL: SEQ ID NO:6) and a humanized variable region of the heavy chain (OH: SEQ ID NO:8) of an anti-CD3 antibody OKT, and the like.Type: ApplicationFiled: February 25, 2015Publication date: September 28, 2017Applicant: TOHOKU UNIVERSITYInventors: Izumi KUMAGAI, Ryutaro ASANO, Mitsuo UMETSU
-
Publication number: 20170183410Abstract: To provide a high-functional bispecific antibody, especially LH-type bispecific antibody that has further improved its function while maintaining the excellent cytotoxicity such as anti-tumor activity. A bispecific antibody for human EGF receptor 1 and CD3, comprising a variable region comprising a humanized variable region of the light chain (5L: SEQ ID NO:2) and a humanized variable region of the heavy chain (5H: SEQ ID NO:4) of an anti-human EGF receptor 1 antibody 528, and a humanized variable region of the light chain (OL: SEQ ID NO:6) and of a humanized variable region of the heavy chain (OH: SEQ ID NO:8) of an anti-CD3 antibody OKT; a hinge region; and an Fc region, characterized by that the Fc region is originated from human IgG2 sub-class.Type: ApplicationFiled: February 25, 2015Publication date: June 29, 2017Applicant: TOHOKU UNIVERSITYInventors: Izumi KUMAGAI, Ryutaro ASANO, Mitsuo UMETSU
-
Publication number: 20160115233Abstract: [Problem] The purpose of the present invention is to provide a bispecific antibody that is structurally stable, and can show alone a sufficient effect without the co-administration of activated lymphocyte (T-LAK). [Solution] The present invention is therefore related to a humanized highly functional bispecific antibody comprising humanized variable regions of the heavy chain (5H) and the light chain (5L) of an anti-human EGF receptor 1 antibody 528, and humanized variable regions of the heavy chain (OH) and the light chain (OL) of an anti-CD3 antibody OKT3; and having one of the following structures (i)-(vi) in claim 1, wherein the 5H, 5L, OH and OL have an amino acid sequence represented by SEQ ID Nos 25, 26, 27 and 28, respectively.Type: ApplicationFiled: January 8, 2016Publication date: April 28, 2016Applicant: TOHOKU UNIVERSITYInventors: Izumi Kumagai, Ryutaro Asano
-
Patent number: 9315584Abstract: Provided are a novel diabody type bispecific antibody, the function of which as a bispecific antibody is improved to provide a higher additional value, such as cost saving caused by a reduction in dose, to a drug; and a method for producing the same. A humanized diabody type bispecific antibody (LH-diabody type bispecific antibody) characterized in that an L-chain is located in the N-terminal side in each polypeptide (LH type); a humanized high-functional bispecific antibody which contains said LH diabody type bispecific antibody; a nucleic acid molecule encoding both of two kinds of single-stranded polypeptides constituting said bispecific antibody; and a method for producing said antibody which comprises culturing a host cell having been transformed by an expression vector containing said nucleic acid molecule.Type: GrantFiled: January 4, 2010Date of Patent: April 19, 2016Assignee: TOHOKU UNIVERSITYInventors: Izumi Kumagai, Ryutaro Asano, Mitsuo Umetsu
-
Patent number: 9315578Abstract: [Problem] The purpose of the present invention is to provide a bispecific antibody that is structurally stable, and can show alone a sufficient effect without the co-administration of activated lymphocyte (T-LAK). [Solution] The present invention is therefore related to a humanized highly functional bispecific antibody comprising humanized variable regions of the heavy chain (5H) and the light chain (5L) of an anti-human EGF receptor 1 antibody 528, and humanized variable regions of the heavy chain (OH) and the light chain (OL) of an anti-CD3 antibody OKT3; and having one of the following structures (i)-(vi) in Claim 1, wherein the 5H, 5L, OH and OL have an amino acid sequence represented by SEQ ID Nos 25, 26, 27 and 28, respectively.Type: GrantFiled: October 16, 2006Date of Patent: April 19, 2016Assignee: TOHOKU UNIVERISTYInventors: Izumi Kumagai, Ryutaro Asano
-
Publication number: 20150322156Abstract: The purpose of the present invention is to provide fragments of humanized anti-EGFR antibody substituted-lysine light-chain or heavy-chain variable regions, and single-chain antibodies, etc, comprising the same, having sufficient binding activity (affinity) with target cells, and having the ability to undergo various site-specific and uniform chemical modifications. The present invention pertains to a humanized variable region on the light-chain or heavy-chain of antibody 528 against human epidermal cell growth factor receptor 1 (Her-1), said variable region comprising the amino acid sequence represented by SEQ ID NO: 2 or SEQ ID NO: 4, wherein fragments of humanized anti-EGFR antibody lysine-substituted light-chain variable regions are formed by substituting a different amino acid for all of the lysine residues, or all of the lysine residues except for the lysine residue(s) of one specified moiety.Type: ApplicationFiled: July 27, 2015Publication date: November 12, 2015Applicant: TOHOKU UNIVERSITYInventors: Izumi KUMAGAI, Takeshi NAKANISHI, Hideaki SANADA, Ryutaro ASANO, Mitsuo UMETSU
-
Patent number: 9139650Abstract: The purpose of the present invention is to provide fragments of humanized anti-EGFR antibody substituted-lysine light-chain or heavy-chain variable regions, and single-chain antibodies, etc, comprising the same, having sufficient binding activity (affinity) with target cells, and having the ability to undergo various site-specific and uniform chemical modifications. The present invention pertains to a humanized variable region on the light-chain or heavy-chain of antibody 528 against human epidermal cell growth factor receptor 1 (Her-1), said variable region comprising the amino acid sequence represented by SEQ ID NO: 2 or SEQ ID NO: 4, wherein fragments of humanized anti-EGFR antibody lysine-substituted light-chain variable regions are formed by substituting a different amino acid for all of the lysine residues, or all of the lysine residues except for the lysine residue(s) of one specified moiety.Type: GrantFiled: July 16, 2011Date of Patent: September 22, 2015Assignee: TOHOKU UNIVERSITYInventors: Izumi Kumagai, Takeshi Nakanishi, Hideaki Sanada, Ryutaro Asano, Mitsuo Umetsu
-
Publication number: 20150175713Abstract: Provided are a novel diabody type bispecific antibody, the function of which as a bispecific antibody is improved to provide a higher additional value, such as cost saving caused by a reduction in dose, to a drug; and a method for producing the same. A humanized diabody type bispecific antibody (LH-diabody type bispecific antibody) characterized in that an L-chain is located in the N-terminal side in each polypeptide (LH type); a humanized high-functional bispecific antibody which contains said LH diabody type bispecific antibody; a nucleic acid molecule encoding both of two kinds of single-stranded polypeptides constituting said bispecific antibody; and a method for producing said antibody which comprises culturing a host cell having been transformed by an expression vector containing said nucleic acid molecule.Type: ApplicationFiled: January 15, 2015Publication date: June 25, 2015Applicant: TOHOKU UNIVERSITYInventors: Izumi KUMAGAI, Ryutaro ASANO, Mitsuo UMETSU
-
Patent number: 8921525Abstract: [Problem] Disclosed is an antibody that exhibits excellent cytotoxicity and cell growth inhibition and that is based on an anti-human epithelial cell growth factor receptor (1) (Her1) antibody (528). Further disclosed is a method for producing same, and the like. [Solution] The mutant of an H chain humanized variable region (5H) or an L chain humanized variable region (5L) of the anti-human epithelial cell growth factor receptor (1) (Her1) antibody (528) is the aforementioned antibody characterized by having one to a plurality (for example: 1 to 5, or 1 to 3) of amino acid mutations within CDR2. Further disclosed are antibody molecules containing said region, a nucleic acid molecule coding for these polypeptides, a method for producing said antibody molecules, and the like.Type: GrantFiled: November 11, 2010Date of Patent: December 30, 2014Assignee: Tohoku UniversityInventors: Izumi Kumagai, Takeshi Nakanishi, Ryutaro Asano, Mitsuo Umetsu
-
Publication number: 20130274446Abstract: The purpose of the present invention is to provide fragments of humanized anti-EGFR antibody substituted-lysine light-chain or heavy-chain variable regions, and single-chain antibodies, etc, comprising the same, having sufficient binding activity (affinity) with target cells, and having the ability to undergo various site-specific and uniform chemical modifications. The present invention pertains to a humanized variable region on the light-chain or heavy-chain of antibody 528 against human epidermal cell growth factor receptor 1 (Her-1), said variable region comprising the amino acid sequence represented by SEQ ID NO: 2 or SEQ ID NO: 4, wherein fragments of humanized anti-EGFR antibody lysine-substituted light-chain variable regions are formed by substituting a different amino acid for all of the lysine residues, or all of the lysine residues except for the lysine residue(s) of one specified moiety.Type: ApplicationFiled: July 16, 2011Publication date: October 17, 2013Applicant: TOHOKU UNIVERSITYInventors: Izumi Kumagai, Takeshi Nakanishi, Hideaki Sanada, Ryutaro Asano, Mitsuo Umetsu
-
Publication number: 20130131320Abstract: [Problem] Disclosed is an antibody that exhibits excellent cytotoxicity and cell growth inhibition and that is based on an anti-human epithelial cell growth factor receptor (1) (Her1) antibody (528). Further disclosed is a method for producing same, and the like. [Solution] The mutant of an H chain humanized variable region (5H) or an L chain humanized variable region (5L) of the anti-human epithelial cell growth factor receptor (1) (Her1) antibody (528) is the aforementioned antibody characterized by having one to a plurality (for example: 1 to 5, or 1 to 3) of amino acid mutations within CDR2. Further disclosed are antibody molecules containing said region, a nucleic acid molecule coding for these polypeptides, a method for producing said antibody molecules, and the like.Type: ApplicationFiled: November 11, 2010Publication date: May 23, 2013Applicant: TOHOKU UNIVERSITYInventors: Izumi Kumagai, Takeshi Nakanishi, Ryutaro Asano, Mitsuo Umetsu
-
Publication number: 20120095191Abstract: Provided are a novel diabody type bispecific antibody, the function of which as a bispecific antibody is improved to provide a higher additional value, such as cost saving caused by a reduction in dose, to a drug; and a method for producing the same. A humanized diabody type bispecific antibody (LH-diabody type bispecific antibody) characterized in that an L-chain is located in the N-terminal side in each polypeptide (LH type); a humanized high-functional bispecific antibody which contains said LH diabody type bispecific antibody; a nucleic acid molecule encoding both of two kinds of single-stranded polypeptides constituting said bispecific antibody; and a method for producing said antibody which comprises culturing a host cell having been transformed by an expression vector containing said nucleic acid molecule.Type: ApplicationFiled: January 4, 2010Publication date: April 19, 2012Applicant: TOHOKU UNIVERSITYInventors: Izumi Kumagai, Ryutaro Asano, Mitsuo Umetsu
-
Publication number: 20100173360Abstract: The present invention relates to a zinc oxide-binding antibody having high stability and binding activity, and high-throughput sensing technology using the antibody, such as biosensors. Specifically, the present invention relates to a peptide-grafted antibody that contains a zinc oxide-recognizing peptide in the CDR H-1 region of a camel antibody, and a solid support (e.g., a biosensor and a protein chip) containing a zinc oxide layer on which the antibody has been immobilized.Type: ApplicationFiled: February 14, 2008Publication date: July 8, 2010Applicant: TOHOKU UNIVERSITYInventors: Mitsuo Umetsu, Izumi Kumagai, Ryutaro Asano, Takeshi Nakanishi
-
Patent number: 7635475Abstract: The purpose of the present invention is to provide a diabody-type bispecific antibody, which is characterized by having low immunogenicity and high infiltrating activity into tumor tissues, and by being easily mass-produced at a low cost with use of microorganisms, and by being easily altered in function by means of genetic engineering. The diabody-type bispecific antibody shows a more remarkable effect than the conventional diabody-type bispecific antibodies and chemically synthesized bispecific antibodies even in a very low concentration and in the absence of the super antigen.Type: GrantFiled: August 18, 2003Date of Patent: December 22, 2009Assignee: Tohoku Techno Arch Co., Ltd.Inventors: Izumi Kumagai, Toshio Kudo, Kouhei Tsumoto, Ryutaro Asano
-
Publication number: 20090202532Abstract: [Problem]The purpose of the present invention is to provide a bispecific antibody that is structurally stable, and can show alone a sufficient effect without the co-administration of activated lymphocyte (T-LAK). [Solution] The present invention is therefore related to a humanized highly functional bispecific antibody comprising humanized variable regions of the heavy chain (5H) and the light chain (5L) of an anti-human EGF receptor 1 antibody 528, and humanized variable regions of the heavy chain (OH) and the light chain (OL) of an anti-CD3 antibody OKT3; and having one of the following structures (i)-(vi) in Claim 1, wherein the 5H, 5L, OH and OL have an amino acid sequence represented by SEQ ID Nos 25, 26, 27 and 28, respectively.Type: ApplicationFiled: October 16, 2006Publication date: August 13, 2009Applicant: TOHOKU UNIVERSITYInventors: Izumi Kumagai, Ryutaro Asano
-
Publication number: 20060210564Abstract: The purpose of the present invention is to provide a diabody-type bispecific antibody, which is characterized by having low immunogenicity and high infiltrating activity into tumor tissues, and by being easily mass-produced at a low cost with use of microorganisms, and by being easily altered in function by means of genetic engineering. The diabody-type bispecific antibody shows a more remarkable effect than the conventional diabody-type bispecific antibodies and chemically synthesized bispecific antibodies even in a very low concentration and in the absence of the super antigen.Type: ApplicationFiled: August 18, 2003Publication date: September 21, 2006Inventors: Izumi Kumagai, Toshio Kudo, Kouhei Tsumoto, Ryutaro Asano